-
2024-516112-21-00
5
2017-11-20
Newly diagnosed acute myeloid leukaemia (AML), high risk myelodysplast
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2024-513964-24-00
5
2017-09-14
Squamous cell carcinoma, previously untreated
Stage III, stage IVa (op
-
2024-510704-37-00
5
2017-03-22
ER+/HER2- metastatic breast cancer
-
2023-505246-26-00
5
2016-01-27
High- or very-high risk, localized or locally advanced prostate cancer
-
2024-513521-23-00
5
2015-08-19
Prostate Cancer
-
2024-518741-21-00
4
2014-12-23
colon cancer
-
2024-514904-14-00
4
2014-10-08
Patients with metastatic or unresectable locally advanced malignancies
-
2024-511096-15-00
5
2014-08-01
Breast Cancer
-
2024-517622-25-00
5
2013-12-06
Patients with localized prostate cancer and high-risk features of rela
-
2024-516996-34-00
5
2012-04-12
oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
-
2024-514844-10-00
4
2010-03-18
Retinoblastoma
-
2024-519620-24-01
5
2026-06-01
ANCA-associated vasculitis
-
2024-516095-15-00
1
2025-08-05
Kidney Disease
-
2024-516687-28-00
5
2025-06-06
Patients with GPA and inadequate response to standard of care therapy
-
2025-522867-13-00
4
2026-04-27
Non Small Cell Lung Cancer
-
2024-515994-83-00
5
2026-01-13
aneurysmal subarachnoid hemorrhage with a vasospasm
-
2024-518197-14-00
4
2025-09-24
Pediatric respiratory disorder
-
2024-513697-22-00
5
2024-11-07
non-small-cell lung cancer
-
2024-513648-27-00
4
2024-10-25
Patients with newly or active diffuse Systemic sclerosis (SSc) at the
-
2023-508216-29-00
5
2024-10-14
Dental care
-
2024-511363-28-00
5
2024-09-24
hidradenitis suppurativa (HS)
-
2024-511225-64-00
4
2024-09-18
Alopecia areata
-
2023-509001-76-00
5
2024-07-01
Asthma